A cancer diagnosis presents one of the greatest difficulties an individual can face in life. It presents a unique challenge capable of bringing any person to their wit’s end. It is therefore sad that there are pharmaceutical companies out there that manufacture chemotherapy and other cancer management drugs that value profits over the welfare of the patients. If you have been diagnosed with cancer or know a person who has, chances are high that you must have heard about or come across a drug known as Taxotere. What is Taxotere? Taxotere is a cancer-treatment drug that is manufactured and sold by a chief pharmaceutical company known as Sanofi-Aventis. The company is outside France but markets its products globally. The Taxotere drug is particularly used in chemotherapy in the U.S. It is mostly used in the treatment of breast cancer and other types of cancer. The drug is administered intravenously and slows down the rate of cancer cell growth in the patient’s body. When this drug was first introduced in the market, it became the go-to-treatment especially among women suffering from breast cancer. Around 75% of patients suffering from breast cancer were advised to use Taxotere as a way of fighting cancer.
Side Effects of Taxotere
From the information available, the use of Taxotere in chemotherapy results in very unfavorable side effects. A number of common side effects associated with using Taxotere include fatigue, nausea, pain, vomiting etc. The most profound side effect of using the drug is hair loss. Cancer patients experience some sort of hair loss during the course of chemotherapy treatment. The use of Taxotere led to some people suffering from permanent hair loss. In normal circumstances, when a cancer patient loses their hair due to chemotherapy, it usually grows back after the treatment procedure. The use of Taxotere left a lot of patients suffering from permanent hair loss (alopecia), which adversely affects them together with their families.
Despite Sanofi-Aventis being a global company marketing its products throughout the world, it did not warn its customers in the USA of the drug’s potential to cause permanent hair loss. The company had warned its customers in other areas of the potential dangerous side effect but did not issue the same important warning to users in the U.S. This led to a high number of patients using Taxotere without knowing that it had devastative side effects. It was only in 2015 when the FDA issued a warning about the use of Taxotere after several instances of permanent alopecia were reported that people realized its dangerous side effects. Sanofi had indicated on their United States’ labels that the hair lost due to the use of Taxotere would grow back after completion of the treatment. However, a large number of women in the United States suffered permanent hair loss as a result of using Taxotere without getting a clear warning of its effects by the manufacturers. A large number of these affected women filed a taxotere lawsuit against the manufacturer for failing to disclose to them this important information. The lawsuits were in early October consolidated into a Multi-District Litigation (MDL) proceeding in order to streamline the high number of lawsuits based on similar facts.